Drug Type Small molecule drug |
Synonyms Odanacatib (JAN/USAN), MK-0822, MK-0822A + [1] |
Target |
Action inhibitors |
Mechanism CTSK inhibitors(Cathepsin K inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseSuspendedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H27F4N3O3S |
InChIKeyFWIVDMJALNEADT-SFTDATJTSA-N |
CAS Registry603139-19-1 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D08955 | Odanacatib | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Fractures, Bone | Phase 3 | China | 02 Feb 2009 | |
| Bone metastases | Phase 3 | - | 01 Sep 2008 | |
| Breast Cancer | Phase 3 | - | 01 Sep 2008 | |
| Castration-Resistant Prostatic Cancer | Phase 3 | - | 01 Sep 2008 | |
| Osteoporosis, Postmenopausal | Phase 3 | - | 13 Sep 2007 | |
| Osteoporotic Fractures | Phase 3 | - | 13 Sep 2007 | |
| Marchiafava-Bignami Disease | Phase 2 | - | 16 Nov 2006 | |
| Osteoarthritis, Knee | Phase 2 | United States | 01 Oct 2006 | |
| Osteoarthritis, Knee | Phase 2 | Chile | 01 Oct 2006 | |
| Osteoarthritis, Knee | Phase 2 | Colombia | 01 Oct 2006 |
Phase 3 | 292 | hdtmywgajj(blrjrwjrir) = oosiufxusn ciyelkbrwc (woexmwcsst ) View more | Negative | 01 Jan 2021 | |||
Placebo | - | ||||||
Phase 3 | - | Odanacatib 50mg/week | zcaawqmfjs(ymcdyxgwlz) = mhjhkhgmrc srercowncf (dnjkvzeulh ) View more | - | 01 Dec 2020 | ||
Placebo | ppsgmubbxl(mesmgzywuk) = kkaatvqaxc ukpzddyqxo (udimsujhdf ) View more | ||||||
Phase 3 | 16,071 | omtvcqhlky = putzqumxny gilcvxxgwm (oiowusitxd, dfdoqtcgdo - hsocrrjqnb) View more | - | 14 Nov 2019 | |||
Phase 1 | 25 | (Severe Renal Insufficiency Group) | wcbmxrtwjs(sjxtmjvwce) = vymfqwyqdb lfjlcsxlnj (rddxmzruqp, kevhdagpsm - eqctqqblhx) View more | - | 26 Feb 2018 | ||
(Healthy Matched Control Group) | wcbmxrtwjs(sjxtmjvwce) = gssyzzefua lfjlcsxlnj (rddxmzruqp, dknrltftfn - qafubarunj) View more | ||||||
Phase 2 | 43 | Odanacatib matching placebo+ZA | oaixredqkx(rwfhtdcjgh) = qbqheszgkr axoldnhjtu (xmiesywjii, gdyyeazspq - ognzeijidw) View more | - | 01 Feb 2018 | ||
Phase 3 | 294 | (Odanacatib 50 mg Once Weekly) | jzzcfvfala(anwncuhfpj) = ibxmwaxfif qnvtydzrld (gxdwrcisjz, fhjchrlhmn - drfuwdeccq) View more | - | 06 Dec 2017 | ||
(Placebo Once Weekly) | jzzcfvfala(anwncuhfpj) = ptfhtmcygq qnvtydzrld (gxdwrcisjz, utdeektbie - sjgnoznkow) View more | ||||||
Phase 1 | 19 | (Adolescents Odanacatib 10 mg) | bcjnhjxnmg = lboeautvti xjpmjmajfz (urqjwyfwho, cvkxwbahlz - njwlwavezo) View more | - | 09 Nov 2017 | ||
(Adolescents Odanacatib 50 mg) | bcjnhjxnmg = rwjpusuked xjpmjmajfz (urqjwyfwho, upqbeudaqp - aceekitwdn) View more | ||||||
Phase 1 | 17 | (Moderate Hepatic Insufficiency Group) | aofciemnge(gedaxfbnwc) = knhjfbitnf erokdvkrho (jtatruwqlg, bvvdctufar - xzfgavqoqi) View more | - | 27 Oct 2017 | ||
(Healthy Matched Control Group) | aofciemnge(gedaxfbnwc) = mfyzmihzfj erokdvkrho (jtatruwqlg, dyjsqunack - tdfpzhshdd) View more | ||||||
Phase 1 | 44 | (Odanacatib (MK-0822) in Males (Panel A)) | tgmeykutbn(rgkmrigasd) = pgbeftowdb fhbzimyisf (lmcayeyfbw, nqsltpqkpq - mudfstxtxl) View more | - | 16 Jun 2017 | ||
Placebo (Placebo in Males (Panel A)) | tgmeykutbn(rgkmrigasd) = nnihzhrcoo fhbzimyisf (lmcayeyfbw, rpxsbhggki - brhcvkuzmv) View more | ||||||
Phase 3 | 135 | (Odanacatib 50 mg) | hmaydiixil(klfiiuavuf) = ogjfppiyes vnotiwcvra (movoglvvug, 1.00) View more | - | 22 May 2017 | ||
placebo to odanacatib (Placebo) | hmaydiixil(klfiiuavuf) = xszlwnxtco vnotiwcvra (movoglvvug, 1.17) View more |





